UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 9, 2017

 

The Spectranetics Corporation

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)

 

000-19711
(Commission
File Number)

 

84-0997049
(IRS Employer
Identification No.)

 

9965 Federal Drive
Colorado Springs, Colorado 80921
(Address of principal executive offices) (Zip Code)

 

(719) 633-8333

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Item 1.01               Entry into a Material Definitive Agreement.

 

On June 9, 2017, The Spectranetics Corporation, a Delaware corporation (the “Company”), entered into (i) an amended and restated term credit and security agreement (the “Term Loan Credit Agreement”), dated June 9, 2017 (the “Closing Date”), by and among the Company and AngioScore Inc., as borrowers (jointly, the “Borrowers”), MidCap Financial Trust, as administrative agent (the “Term Administrative Agent”) and as a lender, and the other lenders party thereto and (ii) an amended and restated revolving credit and security agreement (the “Revolving Loan Credit Agreement”, and together with the Term Loan Credit Agreement, the “Credit Agreements”), dated the Closing Date, by and among the Borrowers, MidCap Funding IV Trust, as administrative agent (the “Revolving Administrative Agent” and, together with the Term Administrative Agent, the “Agents”) and the lenders party thereto.  The Credit Agreements replace the Term Credit and Security Agreement (the “Original Term Loan Credit Agreement”) and the Revolving Credit and Security Agreement (the “Original Revolving Loan Credit Agreement and, together with the Original Term Loan Credit Agreement, the “Original Credit Agreements), each dated December 7, 2015, by and among the Borrowers, MidCap Financial Trust, as administrative agent and the other lenders party thereto. The Term Loan Credit Agreement provides for a $90 million term loan facility (the “Term Loan Facility”) and the Revolving Loan Credit Agreement provides for a $50 million revolving loan facility (the “Revolving Loan Facility” and together with the “Term Loan Facility”, the “Facilities”). Both Facilities expire on March 1, 2021. The Revolving Loan Facility may be increased to up to $70 million at the Company’s request and with approval of the Revolving Administrative Agent and the Revolving Loan Facility lenders. The obligations of the Borrowers under the Credit Agreements are secured by a lien on substantially all of the assets of the Borrowers.

 

The Term Loan Facility bears interest at the LIBOR Rate (as defined in the Term Loan Credit Agreement) plus an applicable margin of 7.15% per annum; provided that the applicable margin will be reduced to 5.95% if the Company’s EBITDA (as defined in the Term Loan Credit Agreement) is equal to or greater than $12,500,000 for a specified prior period and certain other conditions are met.  The Borrowers may prepay all or a portion of the Term Loan Facility subject to certain conditions and a prepayment fee of (i) 3.0% of the amount of the Term Loan Facility prepaid in the first year following the Closing Date and (ii) 2.0% of the amount of the Term Loan Facility prepaid thereafter.  The Term Loan Facility is subject to an exit fee of 4.0% of the amount advanced under the Term Loan Facility. Interest-only payments are due during the first 24 months of the Term Loan Facility, with principal payments beginning thereafter in equal monthly installments until maturity.

 

Amounts drawn under the Revolving Loan Facility bear interest at the LIBOR Rate (as defined in the Revolving Loan Credit Agreement) plus 4.45% per annum, while the undrawn portion is subject to an unused line fee of 0.50% per annum. The Revolving Loan Facility is subject to a minimum balance, such that the Borrowers pay the greater of (i) interest accrued on the actual amount drawn under the Revolving Loan Facility and (ii) interest accrued on 50% of the average Borrowing Base (as defined in the Revolving Loan Credit Agreement).

 

Under the Credit Agreements, the Borrowers are required to maintain minimum cash and cash equivalents of no less than $10 million, maintain net revenues in excess of certain specified minimum Net Revenue (as defined in the Credit Agreements) thresholds and make certain customary representations and covenants.  The Credit Agreements also contain customary events of default, including payment and covenant defaults, breaches of certain representations and warranties, cross defaults to certain material indebtedness, certain events of bankruptcy and insolvency, certain events under ERISA, material judgments, breaches of material contracts and events resulting in a material adverse effect. If an event of default occurs and is not cured within any applicable grace period or is not waived, the applicable Agent and the lenders are entitled to take various actions, including, without limitation, the acceleration of amounts due under the applicable Credit Agreement, the suspension or termination of commitments under the Credit Agreements and the exercise of remedies under the Uniform Commercial Code with respect to the collateral securing the obligations of the Borrowers under the Credit Agreements.  Upon the occurrence of an event of default, the Borrowers’ obligations under the Credit Agreements may at the election of the applicable Agent or the lenders, or in the event of insolvency or bankruptcy will automatically, bear interest at rates that are 2.0% per annum in excess of the rates otherwise payable under the Credit Agreements.

 

The Company drew $90 million under the Term Loan Facility and approximately $30.8 million under the Revolving Loan Facility on the Closing Date. Proceeds from the Term Loan Facility and Revolving Loan Facility were used to refinance approximately $90.8 million outstanding under the Original Credit Agreements, to pay an exit fee under the Original Term Loan Credit Agreement and to pay certain other fees and expenses, and for general working capital and corporate purposes.

 

The foregoing description of the Credit Agreements is qualified in its entirety by reference to the full text of the Credit Agreements, which are filed as Exhibit 10.1 and Exhibit 10.2 to this report and are incorporated by reference herein.

 

Item 2.03              Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

 

2



 

Item 7.01              Regulation FD Disclosure.

 

On June 9, 2017, the Company issued a press release announcing the Company’s entering into the Credit Agreements described above.  A copy of the press release is furnished as Exhibit 99.1 of this report.

 

The information under Item 7.01 and in Exhibit 99.1 of this report is being furnished and not “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information under Item 7.01 and in Exhibit 99.1 of this report are not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01     Financial Statements and Exhibits.

 

(d)     Exhibits.

 

Exhibit No.

 

Description

 

 

 

10.1

 

Amended and Restated Term Credit and Security Agreement, dated as of June 9, 2017, by and among The Spectranetics Corporation and AngioScore Inc., as borrowers, MidCap Financial Trust, as administrative agent and a lender, and the other lenders party thereto.

 

 

 

10.2

 

Amended and Restated Revolving Credit and Security Agreement, dated as of June 9, 2017, by and among The Spectranetics Corporation and AngioScore Inc., as borrowers, MidCap Funding IV Trust, as administrative agent, and the lenders party thereto.

 

 

 

99.1

 

Press Release issued by The Spectranetics Corporation, dated June 9, 2017.

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE SPECTRANETICS CORPORATION

 

 

 

 

Date: June 9, 2017

By:

/s/ Paul Gardon

 

 

Paul Gardon

 

 

Senior Vice President, General Counsel and Corporate Secretary

 

4



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

10.1

 

Amended and Restated Term Credit and Security Agreement, dated as of June 9, 2017, by and among The Spectranetics Corporation and AngioScore Inc., as borrowers, MidCap Financial Trust, as administrative agent and a lender, and the other lenders party thereto.

 

 

 

10.2

 

Amended and Restated Revolving Credit and Security Agreement, dated as of June 9, 2017, by and among The Spectranetics Corporation and AngioScore Inc., as borrowers, MidCap Funding IV Trust, as administrative agent, and the lenders party thereto.

 

 

 

99.1

 

Press Release issued by The Spectranetics Corporation, dated June 9, 2017.

 

5


The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more The Spectranetics Corp. (MM) Charts.
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more The Spectranetics Corp. (MM) Charts.